Bill > SB1094

This bill expands the ability of pharmacists to substitute biological products for prescribed ones, allowing them to choose a "biosimilar" (a biological product that is highly similar to an already approved biological product) or an "interchangeable" biological product, provided the prescriber doesn't explicitly forbid it and the substitute is not more expensive. It also requires health care service plans and health insurers to continue covering a drug that was previously approved if the patient is still prescribed it and it remains medically necessary and effective, though they can require patients to try a biosimilar or interchangeable product first under certain conditions, such as if it's cheaper and the patient's out-of-pocket costs don't increase. The bill aims to promote the use of equally effective, lower-cost treatments for prescription drugs.

Business and Industry

https://leginfo.legislature.ca.gov/faces/billStatusClient.xhtml?bill_id=202520260SB1094